Literature DB >> 17562297

Saxatilin suppresses tumor-induced angiogenesis by regulating VEGF expression in NCI-H460 human lung cancer cells.

Yoon-Jung Jang1, Dong Seok Kim, Ok-Hee Jeon, Doo-Sik Kim.   

Abstract

Tumor growth and metastasis are dependent on angiogenesis, and endothelial cell invasion and migration are apparent means of regulating tumor progression. We report here that saxatilin, a snake venom-derived disintegrin, suppresses the angiogenesis-inducing properties of NCI-H460 human lung cancer cells. Culture supernatants of NCI-H460 cells are able to induce human umbilical vascular endothelial cell (HUVEC) invasion and tube formation. However, treatment of the cancer cells with saxatilin resulted in reduced angiogenic activity of the culture supernatant. This suppressed angiogenic property was found to be associated with the level of vascular endothelial growth factor (VEGF) in the culture supernatant. Further experimental evidence indicated that saxatilin inhibits VEGF production in NCI-H460 cells by affecting hypoxia induced factor-1 alpha (HIF-1 alpha) expression via the Akt pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17562297     DOI: 10.5483/bmbrep.2007.40.3.439

Source DB:  PubMed          Journal:  J Biochem Mol Biol        ISSN: 1225-8687


  14 in total

1.  H460 non-small cell lung cancer stem-like holoclones yield tumors with increased vascularity.

Authors:  Eugene Manley; David J Waxman
Journal:  Cancer Lett       Date:  2013-12-12       Impact factor: 8.679

2.  cDNA cloning of a snake venom metalloproteinase from the eastern diamondback rattlesnake (Crotalus adamanteus), and the expression of its disintegrin domain with anti-platelet effects.

Authors:  Montamas Suntravat; Ying Jia; Sara E Lucena; Elda E Sánchez; John C Pérez
Journal:  Toxicon       Date:  2013-01-10       Impact factor: 3.033

3.  Correlation of matrix metalloproteinase suppressor genes RECK, VEGF, and CD105 with angiogenesis and biological behavior in esophageal squamous cell carcinoma.

Authors:  Sheng-Lei Li; Dong-Ling Gao; Zhi-Hua Zhao; Zong-Wen Liu; Qiu-Min Zhao; Jin-Xia Yu; Kui-Sheng Chen; Yun-Han Zhang
Journal:  World J Gastroenterol       Date:  2007-12-07       Impact factor: 5.742

Review 4.  Snake venom disintegrins and cell migration.

Authors:  Heloisa S Selistre-de-Araujo; Carmen L S Pontes; Cyntia F Montenegro; Ana Carolina B M Martin
Journal:  Toxins (Basel)       Date:  2010-10-29       Impact factor: 4.546

5.  NAHA, a novel hydroxamic acid-derivative, inhibits growth and angiogenesis of breast cancer in vitro and in vivo.

Authors:  Jiahua Jiang; Anita Thyagarajan-Sahu; Viktor Krchňák; Andrej Jedinak; George E Sandusky; Daniel Sliva
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

6.  Phellinus linteus suppresses growth, angiogenesis and invasive behaviour of breast cancer cells through the inhibition of AKT signalling.

Authors:  D Sliva; A Jedinak; J Kawasaki; K Harvey; V Slivova
Journal:  Br J Cancer       Date:  2008-03-25       Impact factor: 7.640

7.  Reduction of metastatic and angiogenic potency of malignant cancer by Eupatorium fortunei via suppression of MMP-9 activity and VEGF production.

Authors:  Aeyung Kim; Minju Im; Nam-Hui Yim; Jin Yeul Ma
Journal:  Sci Rep       Date:  2014-11-11       Impact factor: 4.379

Review 8.  Disintegrins from snake venoms and their applications in cancer research and therapy.

Authors:  Jéssica Kele Arruda Macêdo; Jay W Fox; Mariana de Souza Castro
Journal:  Curr Protein Pept Sci       Date:  2015       Impact factor: 3.272

9.  Ethanol extract of Lophatheri Herba exhibits anti-cancer activity in human cancer cells by suppression of metastatic and angiogenic potential.

Authors:  Aeyung Kim; Minju Im; Min Jung Gu; Jin Yeul Ma
Journal:  Sci Rep       Date:  2016-11-03       Impact factor: 4.379

10.  Anti-angiogenic potential of an ethanol extract of Annona atemoya seeds in vitro and in vivo.

Authors:  Jin-Mu Yi; Jong-Shik Park; Jun Lee; Jin Tae Hong; Ok-Sun Bang; No Soo Kim
Journal:  BMC Complement Altern Med       Date:  2014-09-23       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.